MX2020009579A - Vectores de adn sintetico y metodos de uso. - Google Patents

Vectores de adn sintetico y metodos de uso.

Info

Publication number
MX2020009579A
MX2020009579A MX2020009579A MX2020009579A MX2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A
Authority
MX
Mexico
Prior art keywords
dna vectors
methods
dna
synthetic dna
subject
Prior art date
Application number
MX2020009579A
Other languages
English (en)
Spanish (es)
Inventor
Bruce C Schnepp
Philip R Johnson
Original Assignee
Intergalactic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intergalactic Therapeutics Inc filed Critical Intergalactic Therapeutics Inc
Publication of MX2020009579A publication Critical patent/MX2020009579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2020009579A 2018-03-15 2019-03-15 Vectores de adn sintetico y metodos de uso. MX2020009579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643336P 2018-03-15 2018-03-15
US201862749369P 2018-10-23 2018-10-23
PCT/US2019/022511 WO2019178500A1 (en) 2018-03-15 2019-03-15 Synthetic dna vectors and methods of use

Publications (1)

Publication Number Publication Date
MX2020009579A true MX2020009579A (es) 2020-11-09

Family

ID=67908049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009579A MX2020009579A (es) 2018-03-15 2019-03-15 Vectores de adn sintetico y metodos de uso.

Country Status (10)

Country Link
US (2) US20210002667A1 (enExample)
EP (1) EP3765023A4 (enExample)
JP (3) JP2021516953A (enExample)
KR (1) KR20200132893A (enExample)
CN (2) CN117757842A (enExample)
AU (1) AU2019233901A1 (enExample)
CA (1) CA3092088A1 (enExample)
IL (1) IL276923A (enExample)
MX (1) MX2020009579A (enExample)
WO (1) WO2019178500A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
DK3474760T3 (da) 2016-06-27 2023-03-20 Galvanize Therapeutics Inc Generator og et kateter med en elektrode til at behandle en lungepassage
US20200048716A1 (en) * 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
EP4552592A3 (en) 2017-12-26 2025-06-18 Galvanize Therapeutics, Inc. Optimization of energy delivery for various applications
IL326835A (en) * 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes
CN114007535A (zh) 2019-04-18 2022-02-01 盖乐世公司 用于治疗异常组织的装置、系统和方法
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
CN115348844A (zh) 2020-04-08 2022-11-15 盖能适治疗股份有限公司 脉冲电场波形操作和使用
CN116829691A (zh) 2020-08-04 2023-09-29 盖能适治疗股份有限公司 分子到体内细胞的脉冲电场转移
EP4192572A4 (en) 2020-08-04 2024-08-21 Galvanize Therapeutics, Inc. TRANSFER OF MOLECULES BY PULSED ELECTRIC FIELD TO CELLS IN THE ORGANISM
JP2024509084A (ja) * 2021-02-23 2024-02-29 インターギャラクティック セラピューティクス インコーポレイテッド 核酸ベクター及び使用方法
EP4394043A4 (en) * 2021-08-24 2025-09-03 Cells & Genes Biotech Shanghai Co Ltd CELL MODIFICATION METHOD
AU2022367527A1 (en) * 2021-10-15 2024-05-02 Aldevron, Llc Respiratory delivery of therapeutic agents
KR20250011939A (ko) * 2022-05-13 2025-01-22 아시디엔 테라퓨틱스, 인크. Abca4 트랜스-스플라이싱 분자
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
KR20250034991A (ko) 2022-08-16 2025-03-11 알데브론 엘엘씨 합성 환형 핵산 생산을 위한 무세포 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
CN1264854C (zh) * 1999-05-28 2006-07-19 坎布雷科斯生物科学巴尔的摩公司 Dna纯化方法和纯化的dna
EP1224313A1 (en) * 1999-10-07 2002-07-24 University of Iowa Research Foundation Adeno-associated viruses and uses thereof
EP1317560A4 (en) * 2000-09-08 2005-10-05 Gen Hospital Corp DNA VECTORS WHICH COULD REENGANIZE
US20070196838A1 (en) * 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030082559A1 (en) * 2001-01-19 2003-05-01 David Beach Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences
AU2009231171A1 (en) * 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US8945885B2 (en) * 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
CN102083975A (zh) * 2008-07-03 2011-06-01 利兰·斯坦福青年大学托管委员会 小环dna载体制剂及其制备方法和使用方法
EP2439276A1 (de) * 2010-10-05 2012-04-11 Rentschler Biotechnologie GmbH Verfahren zur semi-synthetischen Herstellung hochreiner "MiniCircle" DNA-Vektoren aus Plasmiden
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US10604771B2 (en) * 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
AU2015264263B2 (en) * 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
EP3250685A1 (en) * 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
AU2016260401B2 (en) * 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
AU2016355343C1 (en) * 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Also Published As

Publication number Publication date
EP3765023A1 (en) 2021-01-20
AU2019233901A1 (en) 2020-09-17
JP2026102885A (ja) 2026-06-23
EP3765023A4 (en) 2022-01-19
JP2021516953A (ja) 2021-07-15
US20210002667A1 (en) 2021-01-07
IL276923A (en) 2020-10-29
WO2019178500A1 (en) 2019-09-19
CN111954528A (zh) 2020-11-17
CN117757842A (zh) 2024-03-26
KR20200132893A (ko) 2020-11-25
CA3092088A1 (en) 2019-09-19
JP2024041819A (ja) 2024-03-27
US20240247284A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2022003291A (es) Vectores de adn sinteticos y metodos de uso.
PH12021550843A1 (en) Nucleic acid constructs and methods of use
EP4671369A3 (en) Treatment of amd using aav2 variant with aflibercept
ZA202307880B (en) Human cytomegalovirus comprising exogenous antigens
MX2025014318A (es) Vector de adenovirus de chimpance util para la administracion de neoantigenos
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
WO2017201527A3 (en) Gene therapy methods for age-related diseases and conditions
EP4310500A3 (en) Methods and compositons for the activation of gamma-delta t-cells
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
MY188290A (en) Gold kiwifruit compositions and methods of preparation and use therefor
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
EP3805385A4 (en) LENTIVIRAL VECTOR AND METHOD FOR DELIVERY OF EXOGENOUS RNA BY THE LENTIVIRAL VECTOR
MX2019006426A (es) Reguladores de tau, y composiciones y metodos para su administracion.
MY206763A (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
MX2022006602A (es) Vacunas de herpesvirus de pavo recombinante y uso de las mismas.
WO2016086227A3 (en) Therapeutic compositions comprising transcription factors and methods of making and using the same
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
IL276424A (en) A special promoter for oligodendrocytes, a special mirna for the plp1 gene, a vector including the above-mentioned promoter and/or mirna, and a pharmaceutical composition including the above-mentioned vector
PH12021551701A1 (en) Liver-specific inducible promoters and methods of use thereof
WO2019204303A3 (en) Compositions and methods for treating duchenne muscular dystrophy
WO2019147979A3 (en) Peptides for angiogenic therapy
MX2017016625A (es) Induccion de la expresion genica usando una mezcla de azucar de alta concentracion.